Wilms' Tumor Clinical Trials

A listing of Wilms' Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 60 clinical trials
Featured trial
AREN0534: Treatment for Patients with Bilateral, Multicentrick or Bilaterally-Predisposed Unilateral Wilms Tumor

AREN0534: Treatment for Patients with Bilateral, Multicentrick or Bilaterally-Predisposed Unilateral Wilms Tumor

  • 316 views
  • 08 Nov, 2020
  • 1 location
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients

In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger

  • 34 views
  • 28 Jan, 2021
  • 1 location
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.

peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms Tumor Gene 1 (WT1) peptides.

  • 0 views
  • 14 Mar, 2021
  • 1 location
DC Vaccination in CML

from bcr/abl, WT-1 (Wilms Tumor Protein) and proteinase-3. Monitoring of T cell reactivity against these peptides can then serve as surrogate marker for anti leukemic immunity induced by the vaccine

leukemia
remission
residual tumor
tyrosine
bcr-abl protein
  • 8 views
  • 16 Aug, 2021
  • 2 locations
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.

  • 0 views
  • 10 Apr, 2022
  • 1 location
Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

Trial participants are randomised within 14 days after liver transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus® (test arm) or Advagraf® (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals …

  • 0 views
  • 30 May, 2022
  • 15 locations
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms

  • 0 views
  • 30 May, 2022
  • 92 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

vemurafenib
bone marrow procedure
bone marrow infiltration
chemotherapeutic agents
anti-cancer agents
  • 1032 views
  • 25 Jul, 2022
  • 106 locations
  • 0 views
  • 22 Mar, 2022
  • 7 locations
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first …

hu3f8
bone marrow procedure
high-risk neuroblastoma
monoclonal antibodies
colony stimulating factor
  • 159 views
  • 23 Mar, 2022
  • 23 locations